Lothar Steidler

Summary

Affiliation: Ghent University
Country: Belgium

Publications

  1. ncbi Treatment of murine colitis by Lactococcus lactis secreting interleukin-10
    L Steidler
    Department of Molecular Biology, Ghent University and Flanders Interuniversity Institute for Biotechnology, K L Ledeganckstraat 35, 9000 Gent, Belgium
    Science 289:1352-5. 2000
  2. ncbi In situ delivery of cytokines by genetically engineered Lactococcus lactis
    Lothar Steidler
    VIB Ghent University, Department of Molecular Biology, KL Ledeganckstraat 35, B 9000 Gent, Belgium
    Antonie Van Leeuwenhoek 82:323-31. 2002
  3. ncbi Lactococcus lactis, a tool for the delivery of therapeutic proteins treatment of IBD
    L Steidler
    Department of Molecular Biology, VIB, Ghent University, Ghent
    ScientificWorldJournal 1:216-7. 2001
  4. ncbi Development of an enteric-coated formulation containing freeze-dried, viable recombinant Lactococcus lactis for the ileal mucosal delivery of human interleukin-10
    Nathalie Huyghebaert
    Laboratory of Pharmaceutical Technology, Ghent University, Ghent, Belgium
    Eur J Pharm Biopharm 60:349-59. 2005
  5. ncbi Paracellular entry of interleukin-10 producing Lactococcus lactis in inflamed intestinal mucosa in mice
    Anouk Waeytens
    Department of Pathology, Ghent University, Ghent, Belgium
    Inflamm Bowel Dis 14:471-9. 2008
  6. ncbi Evaluation of extrusion/spheronisation, layering and compaction for the preparation of an oral, multi-particulate formulation of viable, hIL-10 producing Lactococcus lactis
    Nathalie Huyghebaert
    Laboratory of Pharmaceutical Technology, Ghent University, Ghent, Belgium
    Eur J Pharm Biopharm 59:9-15. 2005
  7. ncbi Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10
    Lothar Steidler
    Department of Molecular Biomedical Research, Vlaams Interuniversitair Instituut voor Biotechnologie, Ghent University, KL Ledeganckstraat 35, B 9000 Ghent, Belgium
    Nat Biotechnol 21:785-9. 2003
  8. ncbi Cytokines, chemokines and growth factors in the pathogenesis and treatment of inflammatory bowel disease
    Lothar Steidler
    Department of Molecular Biology, Gheut University and Flanders Interuniversity Institute for Biotechnology, Gent, Belgium
    Adv Exp Med Biol 520:252-85. 2003
  9. ncbi Delivery of therapeutic proteins through Lactococcus lactis
    Sabine Neirynck
    Alimentary Pharmabiotic Centre, Transgenic Bacteriology Group, University College Cork, Western Road, Cork, Ireland
    Biotechnol Genet Eng Rev 22:253-66. 2006
  10. ncbi Delivery of therapeutic proteins to the mucosa using genetically modified microflora
    Lothar Steidler
    University College Cork, Alimentary Pharmabiotic Centre, Transgenic Bacteriology, Cork, Ireland
    Expert Opin Drug Deliv 2:737-46. 2005

Collaborators

Detail Information

Publications17

  1. ncbi Treatment of murine colitis by Lactococcus lactis secreting interleukin-10
    L Steidler
    Department of Molecular Biology, Ghent University and Flanders Interuniversity Institute for Biotechnology, K L Ledeganckstraat 35, 9000 Gent, Belgium
    Science 289:1352-5. 2000
    ..This approach may lead to better methods for cost-effective and long-term management of IBD in humans...
  2. ncbi In situ delivery of cytokines by genetically engineered Lactococcus lactis
    Lothar Steidler
    VIB Ghent University, Department of Molecular Biology, KL Ledeganckstraat 35, B 9000 Gent, Belgium
    Antonie Van Leeuwenhoek 82:323-31. 2002
    ..Therefore it can be attributed to the active in vivo delivery of IL-10. We have further documented this by demonstrating in situ de novo synthesis of IL-10 in the colon of IL-10 -/- mice...
  3. ncbi Lactococcus lactis, a tool for the delivery of therapeutic proteins treatment of IBD
    L Steidler
    Department of Molecular Biology, VIB, Ghent University, Ghent
    ScientificWorldJournal 1:216-7. 2001
    ....
  4. ncbi Development of an enteric-coated formulation containing freeze-dried, viable recombinant Lactococcus lactis for the ileal mucosal delivery of human interleukin-10
    Nathalie Huyghebaert
    Laboratory of Pharmaceutical Technology, Ghent University, Ghent, Belgium
    Eur J Pharm Biopharm 60:349-59. 2005
    ..1 and 44.3% of initial viability after storage for 1 year at 8 and -20 degrees C, respectively, as well as its hIL-10 producing capacity...
  5. ncbi Paracellular entry of interleukin-10 producing Lactococcus lactis in inflamed intestinal mucosa in mice
    Anouk Waeytens
    Department of Pathology, Ghent University, Ghent, Belgium
    Inflamm Bowel Dis 14:471-9. 2008
    ..At present, many aspects of the exact mechanism by which the beneficial effect of the IL-10-producing L. lactis on the mucosa is mediated remain to be clarified...
  6. ncbi Evaluation of extrusion/spheronisation, layering and compaction for the preparation of an oral, multi-particulate formulation of viable, hIL-10 producing Lactococcus lactis
    Nathalie Huyghebaert
    Laboratory of Pharmaceutical Technology, Ghent University, Ghent, Belgium
    Eur J Pharm Biopharm 59:9-15. 2005
    ..lactis in the layering suspension did not significantly change viability after layering and storage. Interleukin-10 production capacity of L. lactis Thy12 was maintained after layering...
  7. ncbi Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10
    Lothar Steidler
    Department of Molecular Biomedical Research, Vlaams Interuniversitair Instituut voor Biotechnologie, Ghent University, KL Ledeganckstraat 35, B 9000 Ghent, Belgium
    Nat Biotechnol 21:785-9. 2003
    ..lactis strain acquired an intact thyA gene from a donor such as L. lactis subsp. cremoris, the transgene would be eliminated from the genome...
  8. ncbi Cytokines, chemokines and growth factors in the pathogenesis and treatment of inflammatory bowel disease
    Lothar Steidler
    Department of Molecular Biology, Gheut University and Flanders Interuniversity Institute for Biotechnology, Gent, Belgium
    Adv Exp Med Biol 520:252-85. 2003
  9. ncbi Delivery of therapeutic proteins through Lactococcus lactis
    Sabine Neirynck
    Alimentary Pharmabiotic Centre, Transgenic Bacteriology Group, University College Cork, Western Road, Cork, Ireland
    Biotechnol Genet Eng Rev 22:253-66. 2006
  10. ncbi Delivery of therapeutic proteins to the mucosa using genetically modified microflora
    Lothar Steidler
    University College Cork, Alimentary Pharmabiotic Centre, Transgenic Bacteriology, Cork, Ireland
    Expert Opin Drug Deliv 2:737-46. 2005
    ..This concept is being developed for the delivery of proteins to the intestine, but has also been applied in delivery to the vagina, nose and mouth...
  11. ncbi Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice
    Klaas Vandenbroucke
    Department for Molecular Biomedical Research, Flanders Interuniversity Institute for Biotechnology and Ghent University, Belgium
    Gastroenterology 127:502-13. 2004
    ..lactis. This novel approach may lead to effective management of acute and chronic colitis and epithelial damage in humans...
  12. ncbi A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease
    Henri Braat
    Department of Experimental Internal Medicine, Academic Medical Centre, Amsterdam, The Netherlands
    Clin Gastroenterol Hepatol 4:754-9. 2006
    ..This novel strategy avoids systemic side effects and is biologically contained; therefore it is suitable as maintenance treatment for chronic intestinal disease...
  13. ncbi Intracellular accumulation of trehalose protects Lactococcus lactis from freeze-drying damage and bile toxicity and increases gastric acid resistance
    Sofie Termont
    Department for Molecular Biomedical Research, Flanders Interuniversity Institute for Biotechnology (VIB) and Ghent University, Technologiepark 927, B-9052 Ghent, Belgium
    Appl Environ Microbiol 72:7694-700. 2006
    ..The newly acquired properties should enable a larger proportion of the administered bacteria to reach the gastrointestinal tract in a bioactive form, providing a means for more effective mucosal delivery of therapeutics...
  14. ncbi Therapeutic drug delivery by genetically modified Lactococcus lactis
    Lothar Steidler
    Alimentary Pharmabiotic Centre, Transgenic Bacteriology, University College Cork, Western Road, Cork, Ireland
    Ann N Y Acad Sci 1072:176-86. 2006
    ..quot; This accomplishment has created the possibility of using this strategy for application in human medicine...
  15. ncbi Oral administration of an IL-10-secreting Lactococcus lactis strain prevents food-induced IgE sensitization
    Christophe P Frossard
    University Hospital of Geneva, Department of Pediatrics, Geneva, Switzerland
    J Allergy Clin Immunol 119:952-9. 2007
    ..Because tolerance to food is potentially modulated by IL-10, strategies to prevent food allergy should favor an increased delivery of IL-10 to the gut...
  16. ncbi Genetically engineered probiotics
    Lothar Steidler
    Department of Medicine, Alimentary Pharmabiotic Center, University College Cork, Western Road, Cork, Ireland
    Best Pract Res Clin Gastroenterol 17:861-76. 2003
    ..If designed carefully and with absolute attention to biological safety in its broadest sense, the development of genetically modified probiotics has the potential to revolutionize alimentary health...
  17. ncbi Recommendations for improved use of the murine TNBS-induced colitis model in evaluating anti-inflammatory properties of lactic acid bacteria: technical and microbiological aspects
    Benoit Foligne
    Bactériologie des Ecosystémes, Institut Pasteur de Lille, Lille, France
    Dig Dis Sci 51:390-400. 2006
    ....